XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting
Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
The expansion underscores Merck’s commitment to invest more than $70 billion in U.S. research, development and capital projects
Breakthrough expands proactive TB screening from birth to 15 years, ensuring faster and more accurate diagnosis
Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab
Contera Pharma will receive an upfront payment and full research funding for each target under investigation
Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
This new facility strengthens Latin America as a collaborative hub
IKS Health's innovative solution orchestrates a roll out of critical operations functions into a unified and efficient connected workflow
Subscribe To Our Newsletter & Stay Updated
